PT1019050E - Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho - Google Patents

Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho

Info

Publication number
PT1019050E
PT1019050E PT98929232T PT98929232T PT1019050E PT 1019050 E PT1019050 E PT 1019050E PT 98929232 T PT98929232 T PT 98929232T PT 98929232 T PT98929232 T PT 98929232T PT 1019050 E PT1019050 E PT 1019050E
Authority
PT
Portugal
Prior art keywords
treatment
somatostatin
agonistics
antagonistics
eye
Prior art date
Application number
PT98929232T
Other languages
English (en)
Inventor
Carsten Enggaard Stidsen
Michael Albert Crider
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PT1019050E publication Critical patent/PT1019050E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
PT98929232T 1997-06-24 1998-06-22 Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho PT1019050E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK74797 1997-06-24
US5130097P 1997-06-30 1997-06-30

Publications (1)

Publication Number Publication Date
PT1019050E true PT1019050E (pt) 2002-09-30

Family

ID=26064570

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98929232T PT1019050E (pt) 1997-06-24 1998-06-22 Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho

Country Status (10)

Country Link
EP (1) EP1019050B1 (pt)
JP (1) JP2002515912A (pt)
AT (1) ATE214604T1 (pt)
AU (1) AU7907198A (pt)
DE (1) DE69804332T2 (pt)
DK (1) DK1019050T3 (pt)
ES (1) ES2174447T3 (pt)
PT (1) PT1019050E (pt)
WO (1) WO1998058646A1 (pt)
ZA (1) ZA985410B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
WO2002024659A2 (en) 2000-09-20 2002-03-28 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
ES2313985T3 (es) 2000-09-20 2009-03-16 Schering Corporation Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3.
ES2311544T3 (es) 2000-09-20 2009-02-16 Schering Corp Imidazoles sustituidos como agonistas o antagonistas duales de histamina h1 y h3.
EP1318996B1 (en) 2000-09-20 2004-12-01 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
WO2004039403A1 (ja) * 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. 角膜障害治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912551A1 (en) * 1996-05-14 1999-05-06 Novo Nordisk A/S Somatostatin agonists and antagonists
JP2001502712A (ja) * 1996-10-31 2001-02-27 ノボ ノルディスク アクティーゼルスカブ 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト

Also Published As

Publication number Publication date
AU7907198A (en) 1999-01-04
DE69804332T2 (de) 2002-11-07
DK1019050T3 (da) 2002-07-08
ATE214604T1 (de) 2002-04-15
ZA985410B (en) 1999-01-04
EP1019050A1 (en) 2000-07-19
WO1998058646A1 (en) 1998-12-30
JP2002515912A (ja) 2002-05-28
EP1019050B1 (en) 2002-03-20
ES2174447T3 (es) 2002-11-01
DE69804332D1 (de) 2002-04-25

Similar Documents

Publication Publication Date Title
EP2156833B1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
JP4217832B2 (ja) 角結膜障害の治療剤
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
DK1239774T3 (da) Apparat til behandling af öjensygdomme
EP0743852B1 (en) Treatment of normotensive glaucoma with valsartan
HK1069851A1 (en) Bone morphogenic proteins (bmp), bmp receptors andbmp binding proteins and their use in the diagnosis and treatment of glaucoma
CN1561393A (zh) 用于治疗青光眼的糖原合成酶激酶－3(gsk－3)的抑制剂
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
JP2005523928A5 (pt)
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
PT1019050E (pt) Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
DK1395263T3 (da) 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
Kaneko et al. Additive intraocular pressure-lowering effects of ripasudil with glaucoma therapeutic agents in rabbits and monkeys
US20170246176A1 (en) Phacosclerosis inhibitor
WO2003057214A8 (en) Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
Shimura et al. Choroiditis in systemic lupus erythematosus: systemic steroid therapy and focal laser treatment
WO2002053156A1 (en) Method for treating glaucoma ii b
WO2004047868A1 (ja) Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤
JP2008285478A (ja) アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
US10752593B2 (en) Compounds for use as therapeutically active substances in the treatment of retinal diseases
Zhang et al. Effects of isopropyl unoprostone, latanoprost, and prostaglandin E2 on acute rise of aqueous flare in pigmented rabbits